233 related articles for article (PubMed ID: 28548943)
21. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
22. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
[TBL] [Abstract][Full Text] [Related]
23. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
24. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
[TBL] [Abstract][Full Text] [Related]
26. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
27. Targeted therapy in Xp11 translocation renal cell carcinoma.
Gomolčáková J; Brezinová B; Dubovan P; Jurišová S; Rejlekova K; Chovanec M; Mardiak J; Mego M
Klin Onkol; 2021; 34(2):137-140. PubMed ID: 33906362
[TBL] [Abstract][Full Text] [Related]
28. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
von Roemeling CA; Marlow LA; Wei JJ; Cooper SJ; Caulfield TR; Wu K; Tan WW; Tun HW; Copland JA
Clin Cancer Res; 2013 May; 19(9):2368-80. PubMed ID: 23633458
[TBL] [Abstract][Full Text] [Related]
29. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
30. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
31. First-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinoma.
Li JR; Yang CK; Wang SS; Chen CS; Chiu KY; Cheng CL; Yang CR; Ho HC; Ko JL; Ou YC
Anticancer Res; 2014 Oct; 34(10):5643-7. PubMed ID: 25275068
[TBL] [Abstract][Full Text] [Related]
32. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
Randrup Hansen C; Grimm D; Bauer J; Wehland M; Magnusson NE
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230776
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
34. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
[TBL] [Abstract][Full Text] [Related]
35. Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression.
Chen WJ; Pan XW; Song X; Liu ZC; Xu D; Chen JX; Dong KQ; Di SC; Ye JQ; Gan SS; Wang LH; Zhou W; Cui XG
Cancer Lett; 2024 Jul; 593():216963. PubMed ID: 38768682
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
38. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Hong DS; Gordon MS; Samlowski WE; Kurzrock R; Tannir N; Friedland D; Mendelson DS; Vogelzang NJ; Rasmussen E; Wu BM; Bass MB; Zhong ZD; Friberg G; Appleman LJ
Clin Genitourin Cancer; 2014 Jun; 12(3):167-177.e2. PubMed ID: 24365125
[TBL] [Abstract][Full Text] [Related]
39. Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity.
Stühler V; Bedke J
BMC Med; 2016 Dec; 14(1):201. PubMed ID: 27923360
[TBL] [Abstract][Full Text] [Related]
40. [Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
Miller K; Bergmann L; Doehn C; Gschwend J; Keilholz U
Aktuelle Urol; 2017 Feb; 48(1):72-78. PubMed ID: 28403496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]